Other
xuna
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
Failure Rate
40.0%
2 terminated/withdrawn out of 5 trials
Success Rate
0.0%
-86.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 2
1(33.3%)
N/A
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 2(1)
N/A(1)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT05604742Phase 1Withdrawn
Belimumab for Treatment of cGVHD Following Allo-HCT
Role: lead
NCT05604755Phase 2Withdrawn
Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT
Role: lead
NCT05341050Recruiting
A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML
Role: lead
NCT04526223Not ApplicableUnknown
Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation
Role: lead
NCT05092048Unknown
A Study for PRO of CML in Real Word
Role: lead
All 5 trials loaded